Wednesday, 08 Apr 2020

You are here

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

SELECT-PsA 1 was a Phase 3, double-blind, randomized study with 1705 active psoriatic arthritis (PsA) patients, unresponsive to at least one non-biologic DMARD, who were randomized to received daily placebo, or upadacitinib (15 or 30 mg) for 24 weeks.  The primary endpoint was the ACR20 response at 12 weeks.

Week 12 results:

 

UPA 15

(429)

UPA 30

(423)

PBO

(423)

ACR2071%79%36%
ACR5038%52%13%
ACR7016%25%2%
PASI 7563%62%21%
MDA37%45%12%

 

 

 

 

 

 

 

 

UPA vs placebo (p<0.0001).

Significantly more patients receiving either dose of UPA achieved PASI 75 at week 16 compared to placebo[1].

Radiographic outcomes were assessed; and after 24 weeks, both the 15 mg and 30 mg dose of UPA significantly inhibited radiographic progression compared to placebo (p<0.01).

The safety profile of UPA was consistent with previously reported results across indications, with no new safety risks detected.  Serious infections occurred in 1.2 percent and 2.6 percent of patients in the 15 mg and 30 mg UPA groups, respectively, compared to 0.9 percent in the placebo group and 0.7 percent in the adalimumab group.

There was one case of adjudicated venous thromboembolic events (VTE) in the UPA 30 mg group (0.2 percent), no cases in the UPA 15 mg group, two cases in the adalimumab group (0.5 percent) and one case in the placebo group (0.2 percent).

 

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.